A review.This article discusses about perspective on the origin, resistance, and spread of the emerging human fungal pathogen Candida auris.Although antifungal resistance remains a key feature of most C. auris infections, relatively little is known about resistance mechanisms in C. auris compared to those of other human fungal pathogens.

01 Apr 2019·Antimicrobial Agents and ChemotherapyQ2 · MEDICINE

In VitroActivity of a Novel Antifungal Compound, MYC-053, against Clinically Significant Antifungal-Resistant Strains ofCandida glabrata,Candida auris,Cryptococcus neoformans, andPneumocystisspp

Q2 · MEDICINE

Article

Author: Collins, M. ; Vikina, D. ; Tetz, V. ; Tetz, G.

bioRxiv, Microbiology

In vitro activity of a novel antifungal compound, MYC-053, against clinically significant antifungal-resistant strains of Candida glabrata, Candida auris, Cryptococcus neoformans, and Pneumocystis spp

Author: Collins, M. ; Tetz, G. ; Vikina, D. ; Tetz, V.

An urgent need exists for new antifungal compounds to treat fungal infections in immunocompromised patients.The aim of the current study was to investigate the potency of a novel antifungal compound, MYC-053, against the emerging yeast and yeast-like pathogens Candida glabrata, Candida auris, Cryptococcus neoformans, and Pneumocystis spp.MYC-053 was equally effective against the susceptible control strains, clin. isolates, and resistant strains, with the min. inhibitory concentrations (MIC) of 0.125-4.0μg/mL.Notably, unlike other antifungal compounds, MYC-053 was effective against Pneumocystis isolates.MYC-053 was highly effective against preformed 48-h-old yeast biofilms, with the minimal biofilm eradication concentrations equal to 1-4 times MIC.The compound was not cytotoxic against L2 and A549 cell lines at concentrations over 100μg/mL.Further, it possessed no apparent hemolytic activity up to 1000μg/mL (the highest concentration tested).Overall, these data indicated that MYC-053 has a broad therapeutic window and may be developed into a promising antifungal agent for the treatment and prevention of invasive fungal infections caused by yeasts and yeast-like fungi in neutropenic patients.

100 Deals associated with MYC-053

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Candidiasis	Preclinical	United States	National Institutes of Health	-
Candidiasis	Preclinical	United States	TGV-Health, Inc.	-
Cryptococcosis	Preclinical	United States	National Institutes of Health	-
Cryptococcosis	Preclinical	United States	TGV-Health, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

MYC-053

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation